Biological response and cell death signaling pathways modulated by tetrahydroisoquinoline-based aldoximes in human cells.


Journal

Toxicology
ISSN: 1879-3185
Titre abrégé: Toxicology
Pays: Ireland
ID NLM: 0361055

Informations de publication

Date de publication:
01 08 2023
Historique:
received: 25 04 2023
revised: 30 06 2023
accepted: 03 07 2023
medline: 7 8 2023
pubmed: 8 7 2023
entrez: 7 7 2023
Statut: ppublish

Résumé

The uncharged 3-hydroxy-2-pyridine aldoximes with protonatable tertiary amines are studied as antidotes in toxic organophosphates (OP) poisoning. Due to some of their specific structural features, we hypothesize that these compounds could exert diverse biological activity beyond their main scope of application. To examine this further, we performed an extensive cell-based assessment to determine their effects on human cells (SH-SY5Y, HEK293, HepG2, HK-2, myoblasts and myotubes) and possible mechanism of action. As our results indicated, aldoxime having a piperidine moiety did not induce significant toxicity up to 300 µM within 24 h, while those with a tetrahydroisoquinoline moiety, in the same concentration range, showed time-dependent effects and stimulated mitochondria-mediated activation of the intrinsic apoptosis pathway through ERK1/2 and p38-MAPK signaling and subsequent activation of initiator caspase 9 and executive caspase 3 accompanied with DNA damage as observed already after 4 h exposure. Mitochondria and fatty acid metabolism were also likely targets of 3-hydroxy-2-pyridine aldoximes with tetrahydroisoquinoline moiety, due to increased phosphorylation of acetyl-CoA carboxylase. In silico analysis predicted kinases as their most probable target class, while pharmacophores modeling additionally predicted the inhibition of a cytochrome P450cam. Overall, if the absence of significant toxicity for piperidine bearing aldoxime highlights the potential of its further studies in medical counter-measures, the observed biological activity of aldoximes with tetrahydroisoquinoline moiety could be indicative for future design of compounds either in a negative context in OP antidotes design, or in a positive one for design of compounds for the treatment of other phenomena like cell proliferating malignancies.

Identifiants

pubmed: 37419273
pii: S0300-483X(23)00174-9
doi: 10.1016/j.tox.2023.153588
pii:
doi:

Substances chimiques

acetaldehyde oxime ME6U10SD7D
Antidotes 0
Oximes 0
3-pyridine-aldoxime 1193-92-6
Organophosphates 0
Pyridines 0
Piperidines 0
Tetrahydroisoquinolines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

153588

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Antonio Zandona (A)

Institute for Medical Research and Occupational Health, POB 291, HR-10001 Zagreb, Croatia.

Josip Madunić (J)

Institute for Medical Research and Occupational Health, POB 291, HR-10001 Zagreb, Croatia.

Katarina Miš (K)

Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Nikola Maraković (N)

Institute for Medical Research and Occupational Health, POB 291, HR-10001 Zagreb, Croatia.

Pierre Dubois-Geoffroy (P)

Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA (UMR 6014), 76000 Rouen, France.

Marco Cavaco (M)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal.

Petra Mišetić (P)

Selvita Ltd., 10001 Zagreb, Croatia.

Jasna Padovan (J)

Selvita Ltd., 10001 Zagreb, Croatia.

Miguel Castanho (M)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal.

Ludovic Jean (L)

Université Paris Cité, CNRS, INSERM, CiTCoM (UMR 8038), F-75006 Paris, France.

Pierre-Yves Renard (PY)

Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA (UMR 6014), 76000 Rouen, France.

Sergej Pirkmajer (S)

Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Vera Neves (V)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal.

Maja Katalinić (M)

Institute for Medical Research and Occupational Health, POB 291, HR-10001 Zagreb, Croatia. Electronic address: mkatalinic@imi.hr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH